Form 8-K
8-K — JOHNSON & JOHNSON
Accession: 0000200406-26-000167
Filed: 2026-08-04
Period: 2026-08-04
CIK: 0000200406
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Financial Statements and Exhibits
Documents
8-K — jnj-20260804.htm (Primary)
EX-99.1 (pressrelease08042026.htm)
GRAPHIC (image_1a.jpg)
GRAPHIC (imagea.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: jnj-20260804.htm · Sequence: 1
jnj-20260804
0000200406false00002004062026-08-042026-08-040000200406us-gaap:CommonStockMember2026-08-042026-08-040000200406jnj:A1.150NotesDueNovember2028Member2026-08-042026-08-040000200406jnj:A2.700NotesDueFebruary2029Member2026-08-042026-08-040000200406jnj:A3.20NotesDueJune2032Member2026-08-042026-08-040000200406jnj:A3.050NotesDueFebruary2033Member2026-08-042026-08-040000200406jnj:A1.650NotesDueMay2035Member2026-08-042026-08-040000200406jnj:A3.350NotesDueJune2036Member2026-08-042026-08-040000200406jnj:A3.350NotesDueFebruary2037Member2026-08-042026-08-040000200406jnj:A3.550NotesDueJune2044Member2026-08-042026-08-040000200406jnj:A3.600NotesDueFebruary2045Member2026-08-042026-08-040000200406jnj:A3.700NotesDueFebruary2055Member2026-08-042026-08-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
August 4, 2026
Johnson & Johnson
(Exact name of registrant as specified in its charter)
New Jersey
1-3215
22-1024240
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $1.00
JNJ
New York Stock Exchange
1.150% Notes Due November 2028
JNJ28
New York Stock Exchange
2.700% Notes Due February 2029
JNJ29B
New York Stock Exchange
3.200% Notes Due June 2032
JNJ32
New York Stock Exchange
3.050% Notes Due February 2033
JNJ33B
New York Stock Exchange
1.650% Notes Due May 2035
JNJ35
New York Stock Exchange
3.350% Notes Due June 2036
JNJ36A
New York Stock Exchange
3.350% Notes Due February 2037
JNJ37B
New York Stock Exchange
3.550% Notes Due June 2044
JNJ44
New York Stock Exchange
3.600% Notes Due February 2045
JNJ45
New York Stock Exchange
3.700% Notes Due February 2055
JNJ55
New York Stock Exchange
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On August 4, 2026, the Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026.
The Company’s related press release is attached to this Report as Exhibit 99.1.
Item 9.01 Financial statements and exhibits
(d) Exhibits.
Exhibit No. Description of Exhibit
99.1
Press Release dated August 4, 2026.
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 4, 2026
JOHNSON & JOHNSON
(Registrant)
By:
/s/ Marc Larkins
Marc Larkins
Corporate Secretary
EX-99.1
EX-99.1
Filename: pressrelease08042026.htm · Sequence: 2
Document
Exhibit 99.1
Media contact:
media-relations@its.jnj.com
Investor contact:
investor-relations@its.jnj.com
For Immediate Release
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
NEW BRUNSWICK, N.J. — August 4, 2026 — Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, the Company’s Innovative Medicine business grew to more than $60 billion in annual revenue and strengthened its position as one of the most respected and successful pharmaceutical businesses in the world.
Jennifer will be succeeded by Tom Cavanaugh who currently serves as Company Group Chairman, North America, Innovative Medicine. Tom brings nearly three decades of biopharmaceutical experience and leadership across therapeutic areas, functions and geographies to the role. Together they will ensure a smooth transition that enables continued success. Tom will join the Johnson & Johnson Executive Committee, effective September 1, 2026.
"Jennifer has made an extraordinary impact on patients, our business, and generations of leaders across our Company," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Her vision, leadership, unwavering commitment to healthcare innovation, and passion for talent development helped define an era of growth and position us for future success.”
Jennifer played a pivotal role in shaping Johnson & Johnson's pharmaceutical business. Throughout her tenure, she impacted nearly every aspect of our Innovative Medicine business—from leading global commercial strategy and acquisitions, to building our therapeutic areas, to transforming our business in North America, and ultimately leading our Innovative Medicine sector as Worldwide Chairman. Her contributions accelerated delivery of new medicines across oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet need, fueling one of the fastest growing companies in the industry. Jennifer strengthened Johnson & Johnson's reputation as an innovation-driven healthcare company and advanced important discussions around healthcare access, innovation and patient outcomes. Recognized for 10 consecutive years among Fortune’s Most Powerful Women, she is widely recognized as a champion for patients and an influential voice across the healthcare industry for improving the lives of millions of patients worldwide.
Tom Cavanaugh joined Johnson & Johnson in 2017, and has held senior leadership positions in Oncology, Immunology and Global Commercial Strategy. Most recently, he led the Company's largest commercial region, driving growth, strengthening execution and advancing organizational excellence. Prior to joining Johnson & Johnson, Tom spent nearly 15 years at Celgene in global product development, global medical affairs, global & regional marketing, and regional management roles in Spain and the U.S. Throughout his career, he has been recognized for his authentic leadership, ability to unite teams around a shared purpose, and commitment to developing talent reflecting both the breadth of his experience and dedication to improving outcomes for patients worldwide.
“I am pleased to appoint Tom to this important role as we advance our pipeline and bring transformative medicines to patients around the world,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson &
Johnson. “I am confident his deep understanding of our business, proven track record of growth, and focus on developing people will ensure we are poised to continue to deliver for patients, healthcare systems, and our company.”
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A list and description of risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
###
GRAPHIC
GRAPHIC
Filename: image_1a.jpg · Sequence: 7
Binary file (244 bytes)
Download image_1a.jpg
GRAPHIC
GRAPHIC
Filename: imagea.jpg · Sequence: 8
Binary file (6614 bytes)
Download imagea.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 10
v3.26.1
Cover
Aug. 04, 2026
Cover [Abstract]
Document Period End Date
Aug. 04, 2026
Document Type
8-K
Entity Registrant Name
Johnson & Johnson
Entity Incorporation, State or Country Code
NJ
Entity File Number
1-3215
Entity Tax Identification Number
22-1024240
Entity Address, Address Line One
One Johnson & Johnson Plaza
Entity Address, City or Town
New Brunswick
Entity Address, State or Province
NJ
Entity Address, Postal Zip Code
08933
City Area Code
732
Local Phone Number
524-0400
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Document Information [Line Items]
Entity Emerging Growth Company
false
Entity Central Index Key
0000200406
Amendment Flag
false
Common Stock
Cover [Abstract]
Title of 12(b) Security
Common Stock, Par Value $1.00
Document Information [Line Items]
Title of 12(b) Security
Common Stock, Par Value $1.00
Trading Symbol
JNJ
Security Exchange Name
NYSE
Trading Symbol
JNJ
Security Exchange Name
NYSE
1.150% Notes Due November 2028
Cover [Abstract]
Title of 12(b) Security
1.150% Notes Due November 2028
Document Information [Line Items]
Title of 12(b) Security
1.150% Notes Due November 2028
Trading Symbol
JNJ28
Security Exchange Name
NYSE
Trading Symbol
JNJ28
Security Exchange Name
NYSE
1.650% Notes Due 2035
Cover [Abstract]
Title of 12(b) Security
1.650% Notes Due May 2035
Document Information [Line Items]
Title of 12(b) Security
1.650% Notes Due May 2035
Trading Symbol
JNJ35
Security Exchange Name
NYSE
Trading Symbol
JNJ35
Security Exchange Name
NYSE
3.20% Notes Due June 2032
Cover [Abstract]
Title of 12(b) Security
3.200% Notes Due June 2032
Document Information [Line Items]
Title of 12(b) Security
3.200% Notes Due June 2032
Trading Symbol
JNJ32
Security Exchange Name
NYSE
Trading Symbol
JNJ32
Security Exchange Name
NYSE
3.350% Notes Due June 2036
Cover [Abstract]
Title of 12(b) Security
3.350% Notes Due June 2036
Document Information [Line Items]
Title of 12(b) Security
3.350% Notes Due June 2036
Trading Symbol
JNJ36A
Security Exchange Name
NYSE
Trading Symbol
JNJ36A
Security Exchange Name
NYSE
3.550% Notes Due June 2044
Cover [Abstract]
Title of 12(b) Security
3.550% Notes Due June 2044
Document Information [Line Items]
Title of 12(b) Security
3.550% Notes Due June 2044
Trading Symbol
JNJ44
Security Exchange Name
NYSE
Trading Symbol
JNJ44
Security Exchange Name
NYSE
2.700% Notes due February 2029
Cover [Abstract]
Title of 12(b) Security
2.700% Notes Due February 2029
Document Information [Line Items]
Title of 12(b) Security
2.700% Notes Due February 2029
Trading Symbol
JNJ29B
Security Exchange Name
NYSE
Trading Symbol
JNJ29B
Security Exchange Name
NYSE
3.050% Notes due February 2033
Cover [Abstract]
Title of 12(b) Security
3.050% Notes Due February 2033
Document Information [Line Items]
Title of 12(b) Security
3.050% Notes Due February 2033
Trading Symbol
JNJ33B
Security Exchange Name
NYSE
Trading Symbol
JNJ33B
Security Exchange Name
NYSE
3.350% Notes due February 2037
Cover [Abstract]
Title of 12(b) Security
3.350% Notes Due February 2037
Document Information [Line Items]
Title of 12(b) Security
3.350% Notes Due February 2037
Trading Symbol
JNJ37B
Security Exchange Name
NYSE
Trading Symbol
JNJ37B
Security Exchange Name
NYSE
3.600% Notes due February 2045
Cover [Abstract]
Title of 12(b) Security
3.600% Notes Due February 2045
Document Information [Line Items]
Title of 12(b) Security
3.600% Notes Due February 2045
Trading Symbol
JNJ45
Security Exchange Name
NYSE
Trading Symbol
JNJ45
Security Exchange Name
NYSE
3.700% Notes due February 2055
Cover [Abstract]
Title of 12(b) Security
3.700% Notes Due February 2055
Document Information [Line Items]
Title of 12(b) Security
3.700% Notes Due February 2055
Trading Symbol
JNJ55
Security Exchange Name
NYSE
Trading Symbol
JNJ55
Security Exchange Name
NYSE
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details
Name:
dei_DocumentInformationLineItems
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDueMay2035Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueJune2032Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueJune2036Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueJune2044Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A2.700NotesDueFebruary2029Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.050NotesDueFebruary2033Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueFebruary2037Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.600NotesDueFebruary2045Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.700NotesDueFebruary2055Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: